Forbes Medi-Tech Continues European Expansion With Product Launch in Finland

Forbes Medi-Tech Inc. (TSX: FMI)(NASDAQ: FMTI) ("Forbes" or "Company") announced the introduction of an innovative processed cheese slice containing the Company's proprietary cholesterol-lowering ingredient, Reducol(TM). Available through the Pirkka Reducol(TM) product range - jointly developed by Kesko Food and Scanvit Ltd. - the processed cheese slices will initially be available in Finland.

With Reducol(TM) already incorporated into a variety of foods - including yoghurts, yoghurt drinks, breads, milk drinks and spreads - European consumers will now be able to include Reducol(TM) cheese slices in meals and snacks, such as grilled cheese and deli sandwiches. Rupp AG, an Austrian-based cheese company with over 100 years' experience in the food industry, will produce the cheese slices containing Reducol(TM).

Related Results

"Drawing upon our vast knowledge of food science and manufacturing processes, we are constantly striving to meet evolving consumer demands and further broaden the range of foods containing Reducol(TM). This processed cheese product containing our cholesterol-lowering ingredient, Reducol(TM), will give consumers even more dietary choices to lower their cholesterol," said Laura Wessman, Senior Vice President, Operations.

About Reducol

Reducol(TM) is a unique ingredient containing plant sterols and stanols, commonly known as phytosterols, which have been clinically proven to significantly lower Low Density Lipoprotein (LDL) or "bad" cholesterol. The ingredient does not change the sensory properties of foods, and can be formulated alone, or in combination with other active ingredients, for dietary supplements. Additional information on Reducol(TM) may be found at: www.reducol.com .

About Forbes Medi-Tech

Forbes Medi-Tech Inc. (TSX: FMI)(NASDAQ: FMTI) is a life sciences company focused on evidence-based nutritional solutions. A leader in nutraceutical technology, Forbes is a provider of value-added products and cholesterol-lowering ingredients for use in functional foods and dietary supplements. Forbes successfully developed and commercialized its Reducol(TM) plant sterol blend, which has undergone clinical trials in various matrices and has been shown to lower "LDL" cholesterol levels safely and naturally. Building upon established partnerships with leading retailers and manufacturers across the globe, Forbes helps its customers to develop private label and branded products. For more information about Forbes Medi-Tech, please visit www.forbesmedi.com .

This News Release contains forward-looking statements and forward-looking information, within the meaning of applicable securities laws (collectively, "forward-looking statements"), regarding the launch of a processed cheese slice containing Reducol(TM), and Forbes' goals. Forward-looking statements can be identified by forward-looking terminology such as "will", "to meet", "further broaden", and similar expressions or variations thereon. Forward-looking statements are inherently uncertain, and actual results may differ materially from the forward-looking statements due to a variety of risks, uncertainties and other factors, including, without limitation, uncertainty whether the processed cheese slices will obtain market acceptance; reliance by the Company on orders for Reducol(TM) by Rupp AG, Kesko Food and Scanvit Ltd.; uncertainty as to sales volumes and revenue; the Company's need for additional future capital, which is not assured; the Company's dependence on a few, and its need for additional, customers; risks inherent in new product development; competition; intellectual property, product liability and insurance risks; manufacturing risks and the Company's dependency on a single manufacturer for its supplies of Reducol(TM); exchange rate fluctuations; and changes in the Company's business strategy or plans. For a further discussion of these and other known risks and uncertainties affecting the Company and its business, please see our latest Annual Information Form / Form 20-F, and other documents filed by us with Canadian and U.S. securities regulatory authorities at www.sedar.com and www.sec.gov . Forward-looking statements are based on the beliefs, assumptions, and expectations of the Company's management at the time they are made, and the Company does not assume any obligation, except as required by law, to update its forward-looking statements if those beliefs, assumptions, or expectations or other circumstances should change.

Reducol(TM) is a trademark of Forbes Medi-Tech Inc.

Contacts: Forbes Medi-Tech Inc. Jodi Regts Director, Investor Relations and Communications (604) 681-8976 Email: jregts@forbesmedi.com Website: www.forbesmedi.com